Sun Pharma appoints Kirti Ganorkar as the Managing Director

Dilip Shanghvi to continue as the Executive Chairman of the Board

Sun Pharma discontinue development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis

Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr

Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items

Sun Pharma to raise stake in US-based Pharmazz to 22.7%

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%

Sun Pharma gets FDA approval for new device to treat skin disease

Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla

US court lifts launch restrictions on Sun Pharma's autoimmune drug

Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise